|
|
Volumn 53, Issue 5, 2009, Pages 1739-1746
|
|
Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIPHENHYDRAMINE;
IDX 899;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
UNCLASSIFIED DRUG;
ABNORMAL DREAMING;
ADULT;
AREA UNDER THE CURVE;
ARTICLE;
CLINICAL TRIAL;
CONTACT DERMATITIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIET RESTRICTION;
DIZZINESS;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
DRUG ABSORPTION;
DRUG BLOOD LEVEL;
DRUG CAPSULE;
DRUG DOSE ESCALATION;
DRUG DOSE REGIMEN;
DRUG EXCRETION;
DRUG EXPOSURE;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG POTENCY;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG URINE LEVEL;
DRUG WITHDRAWAL;
FEMALE;
FOOD DRUG INTERACTION;
HEADACHE;
HUMAN;
HUMAN EXPERIMENT;
HUMAN IMMUNODEFICIENCY VIRUS 1;
MALE;
MAXIMUM PLASMA CONCENTRATION;
MULTIPLE DRUG DOSE;
NAUSEA;
NORMAL HUMAN;
PLASMA CONCENTRATION-TIME CURVE;
POLLAKISURIA;
PRIORITY JOURNAL;
PRURITUS;
RANDOMIZED CONTROLLED TRIAL;
REPEATED DRUG DOSE;
SEX DIFFERENCE;
SINGLE DRUG DOSE;
SKIN DISEASE;
TIME TO MAXIMUM PLASMA CONCENTRATION;
URTICARIA;
VIVID DREAM;
ADOLESCENT;
ADULT;
AGED;
ANTI-HIV AGENTS;
DOUBLE-BLIND METHOD;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HIV REVERSE TRANSCRIPTASE;
HIV-1;
HUMANS;
INDOLES;
MALE;
MIDDLE AGED;
PHOSPHINIC ACIDS;
REVERSE TRANSCRIPTASE INHIBITORS;
TREATMENT OUTCOME;
YOUNG ADULT;
|
|
EID: 66149135193
PISSN: 00664804
EISSN: 10986596
Source Type: Journal
DOI: 10.1128/AAC.01479-08 Document Type: Article |
|
Times cited : (37)
|
|
References (9)
|
